Johnson & Johnson

JNJ Details

JOHNSON & JOHNSON (NYSE: JNJ) is a holding company that is engaged in the research and development, manufacturing, and distribution of a variety of healthcare products. Its operating segments are Consumer, Pharmaceutical and Medical Devices. In Q3FY21, The US accounted for 51.26% of JNJ’s total revenue. As of October 21, 2021, the company's market capitalization stood at USD 430.15 billion.
Latest News:
Q3FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: Price/Earnings Multiple Based Relative Valuation

(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

JNJ Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
JNJ's stock price declined 3.87% in the past three months and is currently leaning towards the higher end of its 52-week range of USD 133.65 to USD 179.92. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 51.05. We have valued the stock using the Price/Earnings-based relative valuation methodology and arrived at a target price of USD 182.18.
Considering the company's growth prospects, solid margins, current valuation, and associated risks, we recommend a "Hold" rating on the stock at the closing price of USD 163.40, as of October 21, 2021.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Newmont Corporation

NEM Details

Newmont Corporation (NYSE: NEM) is a gold mining company engaged in the production and exploration of gold, copper, silver, zinc, and lead. It operates in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. As of October 21, 2021, the company's market capitalization stood at USD 45.69 billion.
Latest News:
Q2FY21 Results:
Key Risks:
Outlook:

Five Year Cost and Production Outlook (+/- 5%) (Source: Q2FY21, Earnings Presentation)
Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

NEM Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
NEM's stock price rose 4.90% in the past month and is currently leaning towards the lower end of its 52-week range of USD 53.03 to USD 75.31. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 57.52. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 63.94.
Considering the company's production outlook, solid margins, current valuation, and associated risks, we recommend a "Hold" rating on the stock at the closing price of USD 57.18 as of October 21, 2021.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Church & Dwight Co., Inc.

CHD Details

Church & Dwight Co., Inc. (NYSE: CHD) is a developer, manufacturer, and distributor of variety of consumer household and personal care products and specialty products focused on animal and food production, chemicals, and cleaners. CHD markets its consumer products via its 13 power brands. As of October 21, 2021, the company's market capitalization stood at USD 20.58 billion.
Latest News:
Q2FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

CHD Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
CHD's stock price declined 1.60% in the past three months and is currently trading close to mid-band of its 52-week range of USD 77.62 to USD 99.53. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 54.62. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 93.01.
Considering the company's sales growth prospects, solid margins, current valuation, and associated risks, we recommend a "Hold" rating on the stock at the closing price of USD 83.80, as of October 21, 2021.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Clean Energy Fuels Corp.

CLNE Details

Clean Energy Fuels Corp. (NASDAQ: CLNE) is a renewable energy company engaged in the procurement and distribution of renewable natural gas (RNG) and conventional natural gas, in the form of compressed natural gas (CNG) and liquefied natural gas (LNG), for the United States and Canadian transportation markets. As of October 21, 2021, the company's market capitalization stood at USD 1.95 billion.
Latest News:
Q2FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation

(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.

CLNE Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
CLNE's stock price rose 12.34% in the past month and is currently leaning towards the lower end of its 52-week range of USD 2.39 to USD 19.79. The stock is currently trading between its 50 and 200 DMA levels, and its RSI Index is at 53.60. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 9.67.
Considering the company's expectation of recovery from COVID-19, current valuation, and associated risks, we recommend a "Hold" rating on the stock at the closing price of USD 8.74, down 2.56% as of October 21, 2021.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Disclaimer
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Past performance is not a reliable indicator of future performance.